セラノスティクスの世界市場レポート 2025

セラノスティクスの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR10.8％で1,857億3,000万米ドルに成長します。予測期間の成長は、精密医療への取り組みの高まり、がん領域以外の用途の拡大、人口の高齢化と慢性疾患、バイオマーカー探索の進歩、政府の支援と資金調達に起因すると考えられます。予測期間の主な動向には、規制当局の支援、コンパニオン診断薬の台頭、がんへの注目の高まりセラノスティクス、患者の関与と意識、技術の融合などがあります。

セラノスティクス市場の予測成長は、がんの有病率の増加によって牽引されると予想されます。がんは、さまざまな臓器に影響を及ぼす制御不能な細胞増殖を特徴とし、世界的に罹患率と死亡率の重要な原因となっています。治療と診断を統合したセラノスティクスは、がんや慢性疾患の管理において大きな可能性を秘めています。このアプローチは、診断能力と治療能力を組み合わせることにより、個別化された標的治療を容易にし、ヘルスケア分野におけるイノベーションを促進します。その結果、がん患者数の増加がセラノスティクス市場の拡大に貢献することになります。例えば、2022年1月現在、米国国立がん研究所（NCI）は、米国人口の約5.4％、1,810万人ががんサバイバーであると報告しています。さらに、2022年には転移性乳がん、前立腺がん、肺がん、大腸がん、膀胱がん、転移性黒色腫を患う人が623,405人おり、2025年には693,452人に増加すると予測されています。このように、がんの有病率の増加はセラノスティクス市場の主要な促進要因となっています。

セラノスティクス市場の成長は、研究開発への投資拡大によっても促進されると予測されています。研究開発（R&D）とは、個人、大学、企業、政府などが、新しい知識を発見したり、新しい製品やプロセスを生み出したり、既存のものを強化したりするために行う一連の活動のことです。セラノスティクスの領域では、研究開発の努力は、画像診断薬と治療薬の両方を疾患組織に特異的に送達し、副作用を最小限に抑え、治療効果を最大化することを目指しています。例えば、2023年4月、米国国立がん研究所（NCI）は、健康な組織を温存しながらがん細胞を分子標的にして排除するために、治療とイメージングを相乗させる急成長分野であるセラノスティクスにおけるエノラーゼの機能を探求するために、43万7,000米ドルの資金を割り当てた。このように、研究開発への投資の増加は、セラノスティクス市場の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界セラノスティクス PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のセラノスティクス市場：成長率分析
• 世界のセラノスティクス市場の実績：規模と成長, 2019-2024
• 世界のセラノスティクス市場の予測：規模と成長, 2024-2029, 2034F
• 世界セラノスティクス総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のセラノスティクス市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 神経疾患
• 心血管疾患
• 免疫疾患
• 腫瘍疾患
• その他の病気
• 世界のセラノスティクス市場：技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ポリメラーゼ連鎖反応
• 免疫組織化学
• インサイチューハイブリダイゼーション
• シーケンシング
• その他のテクノロジー
• 世界のセラノスティクス市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 診断検査室
• その他のエンドユーザー
• 世界のセラノスティクス市場神経疾患のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アルツハイマー病
• パーキンソン病
• 多発性硬化症
• てんかん
• その他の神経疾患
• 世界のセラノスティクス市場、心血管疾患の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 冠動脈疾患
• 心不全
• 心房細動
• 高血圧
• その他の心血管疾患
• 世界のセラノスティクス市場、免疫疾患のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 関節リウマチ
• 全身性エリテマトーデス
• 炎症性腸疾患
• 乾癬
• その他の免疫疾患
• 世界のセラノスティクス市場、腫瘍疾患のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳がん
• 肺がん
• 大腸がん
• 前立腺がん
• その他の腫瘍疾患
• 世界のセラノスティクス市場、その他の疾患のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 感染症
• 代謝障害
• 遺伝性疾患
• その他の病気

第7章 地域別・国別分析

• 世界のセラノスティクス市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のセラノスティクス市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• セラノスティクス市場：競合情勢
• セラノスティクス市場：企業プロファイル
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AmeriPath Inc Overview, Products and Services, Strategy and Financial Analysis
  • Beckman Coulter Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Astellas Pharma
• Helmholtz Centre for Infection Research
• Radiopharm Theranostics Ltd
• Alpha-Theranostics
• UNIVERZITET U NOVOM SADU
• Cardio-Theranostics LLC
• Curium
• SoFi Technologies Inc.
• Theradiag
• Cell Theranostics
• F. Hoffmann-La Roche AG
• GE HealthCare Technologies Inc
• Qiagen NV
• Foundation Medicine Inc
• Leica Biosystems Nussloch GmBH

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• セラノスティクス市場2029：新たな機会を提供する国
• セラノスティクス市場2029：新たな機会を提供するセグメント
• セラノスティクス市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Theranostics is a medical discipline that integrates therapeutics and diagnostics into a unified approach. It entails the development and application of diagnostic tests that not only identify diseases or conditions but also furnish information for guiding personalized therapeutic interventions.

Various types of theranostics are categorized by disease type, encompassing neurological disorders, cardiovascular diseases, immunological disorders, oncology diseases, and others. Neurological disorders comprise a spectrum of conditions affecting the brain, spinal cord, and nerves, leading to diverse symptoms and impairments. Theranostics plays a crucial role in ensuring precise diagnosis, monitoring disease progression, and guiding personalized treatment strategies for these disorders. The technologies employed for theranostics encompass polymerase chain reaction, immunohistochemistry, in-situ hybridization, sequencing, and others. These technologies find application across different end-users, including hospitals and clinics, diagnostic laboratories, and others.

The theranostics market research report is one of a series of new reports from The Business Research Company that provides theranostics market statistics, including the theranostics industry's global market size, regional shares, competitors with a theranostics market share, detailed theranostics market segments, market trends and opportunities, and any further data you may need to thrive in the theranostics industry. This theranostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The theranostics market size has grown rapidly in recent years. It will grow from$111.1 billion in 2024 to $123.33 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. The growth in the historic period can be attributed to advancements in molecular imaging, shift to value-based healthcare, integration in oncology

The theranostics market size is expected to see rapid growth in the next few years. It will grow to $185.73 billion in 2029 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to rise in precision medicine initiatives, expanding applications beyond oncology, population aging and chronic diseases, advancements in biomarker discovery, government support and funding. Major trends in the forecast period include regulatory support, rise of companion diagnostics, increased focus on cancer theranostics, patient engagement and awareness, technological convergence.

The anticipated growth of the theranostics market is expected to be driven by the increasing prevalence of cancer. Cancer, characterized by uncontrolled cell growth affecting various organs, remains a significant source of morbidity and mortality globally. Theranostics, integrating therapeutics and diagnostics, holds substantial promise in cancer and chronic disease management. This approach facilitates personalized and targeted treatments by combining diagnostic and therapeutic capabilities, fostering innovation in the healthcare sector. Consequently, the rise in the number of cancer patients is poised to contribute to the expansion of the theranostics market. For instance, as of January 2022, the National Cancer Institute (NCI) reported that approximately 5.4% of the U.S. population, equivalent to 18.1 million individuals, are cancer survivors. Furthermore, there were 623,405 people living with metastatic breast, prostate, lung, colorectal, or bladder cancer, or metastatic melanoma in 2022, with projections indicating an increase to 693,452 by 2025. Thus, the increasing prevalence of cancer is a key driver for the theranostics market.

The expected growth of the theranostics market is also anticipated to be fueled by the growing investment in research and development. Research and development (R&D) constitute a series of activities conducted by individuals, universities, corporations, and governments to discover new knowledge, create new products or processes, or enhance existing ones. In the realm of theranostics, R&D efforts aim to deliver both imaging and therapeutic agents specifically to diseased tissues, minimizing side effects and maximizing therapeutic efficacy. For instance, in April 2023, the National Cancer Institute (NCI) allocated $437,000 in funds to explore the function of enolase in theranostics, a burgeoning field that synergizes therapy and imaging to molecularly target and eliminate cancer cells while preserving healthy tissue. Thus, the increasing investment in research and development serves as a driving force for the theranostics market.

Major companies in the theranostics market are concentrating on developing advanced solutions, such as theranostics clinical trials, to enhance personalized medicine and improve patient outcomes by integrating diagnostics and therapeutics into a unified treatment approach. Theranostics clinical trials are research studies designed to assess the combined use of diagnostic tests and targeted therapies, tailoring treatment strategies to individual patients. These trials focus on evaluating the effectiveness of specific treatments based on patient-specific biomarkers, thereby advancing personalized medicine. For example, in May 2024, BAMF Health, a cancer treatment center based in the U.S., launched the COMBAT Trial, formally titled "A Phase I/II Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617" (NCT05633160). This trial features a rapid activation process facilitated by BAMF Health's BAMF RapAct program, allowing it to launch in just seven weeks. It also emphasizes the use of innovative radiopharmaceuticals targeting the Gastrin-Releasing Peptide receptor (GRPR), with the goal of improving treatment options for patients with limited therapeutic alternatives.

Major companies in the theranostics market are concentrating on the development of innovative products, including molecular targeted radiopharmaceuticals (MTRP), to gain a competitive advantage. Molecular targeted radiopharmaceuticals are radioactive drugs used for diagnosing and treating diseases, particularly cancer. An example is the launch of 177Lu(n.c.a.)-PSMA-Therapy by Applied Molecular Therapeutics, a US-based biopharmaceutical company, in February 2022. This MTRP specifically targets the PSMA (prostate-specific membrane antigen) protein on the surface of prostate cancer cells, delivering a high radiation dose directly to the tumor while minimizing damage to healthy tissue. The radioactive 177Lu emitted by the therapy kills the cancer cells after binding to the PSMA protein.

In March 2023, Radiopharm Theranostics, an Australia-based biotechnology company specializing in radiopharmaceutical products, acquired Pharma15 Corporation for $4 million. This strategic acquisition positions Radiopharm to explore next-generation radiopharmaceuticals' potential for treating prostate cancer, surpassing PSMA-based therapies, and advancing innovative solutions for patients. Pharma15 Corporation, a US-based pharmaceutical company, specializes in developing radio-immuno-theranostic platforms and pharmaceutical products.

Major companies operating in the theranostics market include Abbott Laboratories, Agilent Technologies Inc., AmeriPath Inc, Beckman Coulter Inc., Thermo Fisher Scientific Inc, Astellas Pharma, Helmholtz Centre for Infection Research, Radiopharm Theranostics Ltd, Alpha- Theranostics, UNIVERZITET U NOVOM SADU, Cardio-Theranostics LLC, Curium, SoFi Technologies Inc., Theradiag, Cell Theranostics, F. Hoffmann-La Roche AG, GE HealthCare Technologies Inc, Qiagen NV, Foundation Medicine Inc, Leica Biosystems Nussloch GmBH, Pfizer Inc., Siemens Healthineers, Advanced Accelerator Applications, AstraZeneca plc, Bayer AG, Bio-Rad Laboratories, The Bristol-Myers Squibb Company, Danaher Corporation, MilliporeSigma, Illumina Inc., Merck KGaA, Roche Diagnostics Corporation, PerkinElmer Inc.

North America was the largest region in the global theranostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the theranostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the theranostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The theranostics market consists of revenues earned by entities by providing genetic testing, targeted therapy services, contract development and manufacturing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The theranostics market also includes of sales of companion diagnostics, nanomedicine and 2D nano-theranostics materials. Values in this market are ""factory gate"" values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Theranostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on theranostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for theranostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The theranostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Neurological Disorders; Cardiovascular Diseases; Immunological Disorders; Oncology Diseases; Other Diseases
• 2) By Technology: Polymerase Chain Reaction; Immunohistochemistry; In-Situ Hybridization; Sequencing; Other Technologies
• 3) By End User: Hospitals And Clinics; Diagnostic Laboratories; Other End Users
• Subsegments:
• 1) By Neurological Disorders: Alzheimer's Disease; Parkinson's Disease; Multiple Sclerosis; Epilepsy; Other Neurological Disorders
• 2) By Cardiovascular Diseases: Coronary Artery Disease; Heart Failure; Atrial Fibrillation; Hypertension; Other Cardiovascular Diseases
• 3) By Immunological Disorders: Rheumatoid Arthritis; Systemic Lupus Erythematosus; Inflammatory Bowel Disease; Psoriasis; Other Immunological Disorders
• 4) By Oncology Diseases: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Other Oncology Diseases
• 5) By Other Diseases: Infectious Diseases; Metabolic Disorders; Genetic Disorders; Other Diseases
• Companies Mentioned: Abbott Laboratories; Agilent Technologies Inc.; AmeriPath Inc; Beckman Coulter Inc.; Thermo Fisher Scientific Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Theranostics Market Characteristics

3. Theranostics Market Trends And Strategies

4. Theranostics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Theranostics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Theranostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Theranostics Market Growth Rate Analysis
• 5.4. Global Theranostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Theranostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Theranostics Total Addressable Market (TAM)

6. Theranostics Market Segmentation

• 6.1. Global Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Neurological Disorders
• Cardiovascular Diseases
• Immunological Disorders
• Oncology Diseases
• Other Diseases
• 6.2. Global Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Polymerase Chain Reaction
• Immunohistochemistry
• In-Situ Hybridization
• Sequencing
• Other Technologies
• 6.3. Global Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Diagnostic Laboratories
• Other End Users
• 6.4. Global Theranostics Market, Sub-Segmentation Of Neurological Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Epilepsy
• Other Neurological Disorders
• 6.5. Global Theranostics Market, Sub-Segmentation Of Cardiovascular Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Coronary Artery Disease
• Heart Failure
• Atrial Fibrillation
• Hypertension
• Other Cardiovascular Diseases
• 6.6. Global Theranostics Market, Sub-Segmentation Of Immunological Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus
• Inflammatory Bowel Disease
• Psoriasis
• Other Immunological Disorders
• 6.7. Global Theranostics Market, Sub-Segmentation Of Oncology Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Other Oncology Diseases
• 6.8. Global Theranostics Market, Sub-Segmentation Of Other Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Infectious Diseases
• Metabolic Disorders
• Genetic Disorders
• Other Diseases

7. Theranostics Market Regional And Country Analysis

• 7.1. Global Theranostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Theranostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Theranostics Market

• 8.1. Asia-Pacific Theranostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Theranostics Market

• 9.1. China Theranostics Market Overview
• 9.2. China Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Theranostics Market

• 10.1. India Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Theranostics Market

• 11.1. Japan Theranostics Market Overview
• 11.2. Japan Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Theranostics Market

• 12.1. Australia Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Theranostics Market

• 13.1. Indonesia Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Theranostics Market

• 14.1. South Korea Theranostics Market Overview
• 14.2. South Korea Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Theranostics Market

• 15.1. Western Europe Theranostics Market Overview
• 15.2. Western Europe Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Theranostics Market

• 16.1. UK Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Theranostics Market

• 17.1. Germany Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Theranostics Market

• 18.1. France Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Theranostics Market

• 19.1. Italy Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Theranostics Market

• 20.1. Spain Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Theranostics Market

• 21.1. Eastern Europe Theranostics Market Overview
• 21.2. Eastern Europe Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Theranostics Market

• 22.1. Russia Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Theranostics Market

• 23.1. North America Theranostics Market Overview
• 23.2. North America Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Theranostics Market

• 24.1. USA Theranostics Market Overview
• 24.2. USA Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Theranostics Market

• 25.1. Canada Theranostics Market Overview
• 25.2. Canada Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Theranostics Market

• 26.1. South America Theranostics Market Overview
• 26.2. South America Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Theranostics Market

• 27.1. Brazil Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Theranostics Market

• 28.1. Middle East Theranostics Market Overview
• 28.2. Middle East Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Theranostics Market

• 29.1. Africa Theranostics Market Overview
• 29.2. Africa Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Theranostics Market Competitive Landscape And Company Profiles

• 30.1. Theranostics Market Competitive Landscape
• 30.2. Theranostics Market Company Profiles
  • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AmeriPath Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Beckman Coulter Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Thermo Fisher Scientific Inc Overview, Products and Services, Strategy and Financial Analysis

31. Theranostics Market Other Major And Innovative Companies

• 31.1. Astellas Pharma
• 31.2. Helmholtz Centre for Infection Research
• 31.3. Radiopharm Theranostics Ltd
• 31.4. Alpha- Theranostics
• 31.5. UNIVERZITET U NOVOM SADU
• 31.6. Cardio-Theranostics LLC
• 31.7. Curium
• 31.8. SoFi Technologies Inc.
• 31.9. Theradiag
• 31.10. Cell Theranostics
• 31.11. F. Hoffmann-La Roche AG
• 31.12. GE HealthCare Technologies Inc
• 31.13. Qiagen NV
• 31.14. Foundation Medicine Inc
• 31.15. Leica Biosystems Nussloch GmBH

32. Global Theranostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Theranostics Market

34. Recent Developments In The Theranostics Market

35. Theranostics Market High Potential Countries, Segments and Strategies

• 35.1 Theranostics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Theranostics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Theranostics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer